Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 19

1.

Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.

Heskamp S, Laverman P, Rosik D, Boschetti F, van der Graaf WT, Oyen WJ, van Laarhoven HW, Tolmachev V, Boerman OC.

J Nucl Med. 2012 Jan;53(1):146-53. doi: 10.2967/jnumed.111.093047. Epub 2011 Dec 15.

2.

Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.

Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, Widmark O, Fant G, Feldwisch J, Tolmachev V.

Bioconjug Chem. 2008 Jan;19(1):235-43. doi: 10.1021/bc700307y. Epub 2007 Dec 29.

PMID:
18163536
3.

Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, Kosterink JG, van Veldhuisen DJ, Sleijfer DT, Jager PL, de Vries EG.

J Clin Oncol. 2006 May 20;24(15):2276-82.

PMID:
16710024
4.

Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.

Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM.

J Nucl Med. 2006 May;47(5):793-6.

5.

Preclinical characterisation of 111In-DTPA-trastuzumab.

Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, Suurmeijer AJ, de Jong S, Jager PL, de Vries EG.

Br J Pharmacol. 2004 Sep;143(1):99-106. Epub 2004 Aug 2.

6.

Selection and characterization of HER2/neu-binding affibody ligands.

Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, Ståhl S.

Protein Eng Des Sel. 2004 May;17(5):455-62. Epub 2004 Jun 18.

PMID:
15208403
7.

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.

Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM.

Nat Biotechnol. 2004 Jun;22(6):701-6. Epub 2004 May 9.

8.

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

Grünwald V, Hidalgo M.

J Natl Cancer Inst. 2003 Jun 18;95(12):851-67. Review.

PMID:
12813169
9.

Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L.

Cancer Res. 2002 Dec 15;62(24):7350-6.

10.
11.

Biology of HER2 and its importance in breast cancer.

Yarden Y.

Oncology. 2001;61 Suppl 2:1-13. Review.

PMID:
11694782
12.
13.

The basic biology of HER2.

Rubin I, Yarden Y.

Ann Oncol. 2001;12 Suppl 1:S3-8. Review.

PMID:
11521719
14.

Growth factor synthesis and human breast cancer progression.

Ethier SP.

J Natl Cancer Inst. 1995 Jul 5;87(13):964-73. Review.

PMID:
7629883
15.

Predictive value of EGF receptor in breast cancer.

Costa S, Stamm H, Almendral A, Ludwig H, Wyss R, Fabbro D, Ernst A, Takahashi A, Eppenberger U.

Lancet. 1988 Nov 26;2(8622):1258. No abstract available.

PMID:
2903994
16.

Expression of epidermal growth factor receptor in human gastric and colonic carcinomas.

Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H, Tahara E.

Cancer Res. 1988 Jan 1;48(1):137-41.

17.

Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents.

Mendelsohn J.

J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):889-92. Review.

PMID:
2285602
18.

Epidermal growth factor.

Carpenter G, Cohen S.

J Biol Chem. 1990 May 15;265(14):7709-12. Review. No abstract available.

19.

Humanization of an anti-p185HER2 antibody for human cancer therapy.

Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM.

Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9.

Supplemental Content

Support Center